By requiring patients to sign the consent form, medical staff can ensure that they have provided adequate information regarding the treatment
5ml added to a 5mg vial yields 1mg/ml
Common side effects that you may experience include tenderness at the injection site, upset stomach and lethargy
VasQ TM has a Breakthrough Device designation effective June 5, 2020, and De Novo classification from FDA effective September 26, 2023, for the indication covered by the Breakthrough Device designation
Our experienced healthcare professionals evaluate the underlying cause of your deficiency, discuss available options, and consider your preferences
Understanding this distinction helps you respond appropriately